TY - T1的潜在治疗靶点肺修复在人类体外< em > < / em >肺灌注JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02222 -2019欧元六世- 55 - 4 SP - 1902222 AU - Wong,亚伦盟——Zamel里卡多AU -杨,乔纳森AU -巴德,加里·d . AU -多斯桑托斯,克劳迪娅c . AU -白,晓惠AU - Wang Yubo盟——Keshavjee井非盟——刘体外肺灌注(exvivo lung perfusion, EVLP)技术已被开发用于评估边缘供肺的功能，并显著提高供肺的利用率。EVLP也被探索为一个平台，通过损伤特异性治疗，如抗生素或纤溶药修复供体肺。我们假设，移植和EVLP之间的活跃表达通路可能揭示了共同的损伤机制和移植前肺修复的潜在治疗靶点。材料和方法回顾性转录组学分析采用了来自“脑死亡后捐赠”肺的外周组织活检，其中有46对移植前/移植后和49对evlp前/移植后。通路分析用于鉴别和比较供体肺对移植和EVLP的反应。结果22条通路在移植中富集，包括上调淋巴细胞活化和细胞死亡以及下调代谢。八种通路在EVLP中富集，包括白细胞功能下调和血管过程上调。27种通路普遍富集，包括先天炎症的激活、细胞死亡、热应激和代谢和蛋白质合成的下调。在炎症簇中，toll样受体/先天免疫信号转导适配器信号具有最大数量的淋巴结，是炎症的中心。 These mechanisms have been previously speculated as major mechanisms of acute lung injury in animal models.Conclusion EVLP and transplantation share common molecular features of injury including innate inflammation and cell death. Blocking these pathways during EVLP may allow for lung repair prior to transplantation.Inflammation and cell death pathways are common molecular features of ischaemia–reperfusion and ischaemia–ex vivo lung perfusion. These may represent therapeutic targets for lung repair prior to transplantation. http://bit.ly/2sIrxOP ER -